Recent Updates
Recently added Catalysts

SAR448632

Phase 1

Undisclosed | Small Molecules | Other |Sanofi|Trials Updated: Nov 18, 2026

SAR448632 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment40

FDA Designations

No designations recorded

SAR448632 clinical trials

SAR448632 · 1 trial · 1 indication

Phase 1 1
NCT07944885First-in-human Study of SAR448632 in Healthy Adult ParticipantsHealthy Volunteer
NOT YET_RECRUITING40 Analytics
PHASE1NOT YET_RECRUITING
First-in-human Study of SAR448632 in Healthy Adult Participants
Healthy VolunteerUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with assessment of Adverse Events (AEs) / Treatment-Emergent Adverse Events (TEAEs), including Injection Site Reactions (ISRs)
Baseline to day 113

Assessment of AEs/TEAEs including ISRs.

Number of participants with potentially clinically significant abnormalities in clinical laboratory evaluation; Vital signs; 12-lead Electrocardiogram.
Baseline to day 113

Clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis); Vital signs; 12-lead ECG (heart rate, PR, QRS, QT, QTcF).

Secondary Endpoints

Maximum observed plasma concentration (Cmax )
Baseline to day 99
Time to reach maximum observed plasma concentration (tmax )
Baseline to day 99
Area under the plasma concentration-time curve (AUC)
Baseline to day 99
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
SAR448632EXPERIMENTALParticipants will receive a single dose of SAR448632 by SC injection or infusion on Day 1 only.
PlaceboPLACEBO_COMPARATORThe placebo administration will match the dosing planned for SAR448632

Interventions

NameTypeDescription
PlaceboDRUGAdministration method will match SAR448632
SAR448632DRUGRoute of administration: SC injection or infusion
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). * Body weight between 45.0 and 95.0 kg, inclusive; Body Mass Index (BMI) between 18.5 and 27.9 kg/m², inclusive. * Contraceptive use by male or female part...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 18, 2026NCT07944885NEW_TRIAL: changed
LOWNov 18, 2026NCT07944885NEW_TRIAL: changed